A game-changer for obesity and heart failure? Dr Pandey reveals breakthrough GLP-1 trial results that show reduced cardiovascular risk and better outcomes for HFpEF patients. Don’t miss this!

Weight-inclusive health care is the provision of equitable care without perpetuating weight stigma among patients of all body ...

Independence Blue Cross began limiting coverage of GLP-1 drugs on Jan. 1 to some medical conditions, but not obesity or weight loss.

Liraglutide, a GLP-1 significantly lowers the rate of recurrent stroke in patients with diabetes, with no apparent increase ...

It’s obvious these drugs are trimming waistlines across the nation; what may be less obvious is that they might also reshape ...

Adam Gilden, MD, MSCE, is an associate director of the Obesity Medicine Fellowship at University of Colorado School of Medicine and associate director of the Colorado University Medicine Weight ...

The overgrown foliage had been hiding an ancient structure. Archaeologists identified the ruins as a pyramid-like building dating back at least 3,800 years, officials said. It has three ...

Background: Despite their potential, Glucagon-like peptide-1 receptor agonists (GLP-1 RA) have not been well studied in cardiac amyloidosis (CA) as randomized trials on GLP-1 RA have excluded patients ...

Semaglutide mimics the action of the natural protein glucagon-like peptide 1(GLP-1), a hormone ... meaning its molecules mimic the structure of GLP-1, binding to its receptor like a counterfeit key ...

Researchers from the Institute of Science Tokyo and Osaka Medical and Pharmaceutical University said that they have developed a peptide that can bind to the spike proteins of SARS-CoV-2 to prevent ...